Adenovirus-mediated expression of bone morphogenetic protein-2 activates titanium particle-induced osteoclastogenesis and this effect occurs in spite of the suppression of TNF-α expression by siRNA

International Journal of Molecular Medicine

Volumn 32, Issue 2, 2013, Pages 403-409

  Sun, Shouxuan ^a   Guo, Haohui ^c   Zhang, Jian ^c   Yu, Bo ^b   Sun, Kening ^a   Jin, Qunhua ^a  

^a AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Adenovirus; Bone Morphogenetic Protein 2; Osteoclast; Small Interfering Rna; Titanium Particles; Tumor Necrosis Factor A

Indexed keywords

ADENOVIRUS BONE MORPHOGENETIC PROTEIN 2 TUMOR NECROSIS FACTOR SMALL INTERFERING RNA; ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TITANIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOVIRIDAE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION; GENETIC VECTORS; MICE; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; RNA, SMALL INTERFERING; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879394978     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1392     Document Type: Article

References (44)

1. Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ and Glant TT: Osteolysis: Basic science. Clin Orthop Rel Res 393: 71-77, 2001. (Pubitemid 33101699)
2. Ingham E and Fisher J: The role of macrophages in osteolysis of total joint replacement. Biomaterials 26: 1271-1286, 2005. (Pubitemid 39314501)
3. Haynes DR, Crotti TN, Potter AE, et al: The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 83: 902-911, 2001. (Pubitemid 32785565)
4. Kobayashi A, Freeman MA, Bonfield W, et al: Number of polyethylene particles and osteolysis in total joint replacements. A quantitative study using a tissue-digestion method. J Bone Joint Surg Br 79: 844-848, 1997. (Pubitemid 27434511)
5. Sabokbar A, Fujikawa Y, Neale S, Murray DW and Athanasou NA: Human arthroplasty derived macrophages differentiate into osteoclastic bone resorbing cells. Ann Rheum Dis 56: 414-420, 1997. (Pubitemid 27345260)
6. Sabokbar A, Pandey R and Athanasou NA: The effect of particle size and electrical charge on macrophage-osteoclast differentiation and bone resorption. J Mater Sci Mater Med 14: 731-738, 2003. (Pubitemid 37047066)
7. González O, Smith RL and Goodman SB: Effect of size, concentration, surface area, and volume of polymethylmethacrylate particles on human macrophages in vitro. J Biomed Mater Res 30: 463-473, 1996. (Pubitemid 26107079)
8. O'Keefe RJ, Rosier RN, Teot LA, Stewart JM and Hicks DG: Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J 18: 26-34, 1998.
9. Xu JW, Konttinen YT, Lassus J, Natah S, Ceponis A and Solovieva S: Tumor necrosis factor-alpha (TNF-alpha) in loosening of total hip replacement (THR). Clin Exp Rheumatol 14: 643-648, 1996. (Pubitemid 27013351)
10. Ross FP: RANKing the importance of measles virus in Paget's disease. J Clin Invest 105: 555-558, 2000. (Pubitemid 30146498)
11. Kobayashi K, Takahashi N, Jimi E, et al: Tumor necrosis factor-α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKLRANK interaction. J Exp Med 191: 275-286, 2000.
12. Azuma Y, Kaji K, Katogi R, Takeshita S and Kudo A: TNFα induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275: 4858-4864, 2000. (Pubitemid 30108878)
13. Qin CQ, Ding Y, Huang DS, Xu J, Ma RF and Huang JB: Down-regulation of TNF-alpha by small interfering RNA inhibits particle-induced Inflammation in vitro. Artif Organs 35: 706-714, 2000.
14. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B and Kjems J: Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 17: 162-168, 2009.
15. Suzuki A, Thies RS, Yamaji N, Song JJ, Wozney JM and Murakami K: A truncated bone morphogenetic protein receptor affects dorsal-ventral patterning in the early Xenopus embryo. Proc Natl Acad Sci USA 91: 10255-10259, 1994. (Pubitemid 24328975)
16. Yamaji N, Celeste AJ, Thies RS, et al: A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4. Biochem Biophys Res Commun 205: 1944-1951, 1994.
17. Abe E, Yamamoto M, Taguchi Y, et al: Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: Antagonism by noggin. J Bone Miner Res 15: 663-673, 2000. (Pubitemid 30174020)
18. Wutzl A, Brozek W, Lernbass I, et al: Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A 77: 75-83, 2006.
19. Jensen ED, Pham L, Billington CJ Jr, et al: Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem 109: 672-682, 2010.
20. Giannoudis PV, Kanakaris NK and Einhorn TA: Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: Review of the existing evidence. Osteoporos Int 18: 1565-1581, 2007. (Pubitemid 47620320)
21. Falany ML, Thames AM III, McDonald JM, et al: Osteoclasts secrete the chemotactic cytokine mim-1. Biochem Biophys Res Commun 281: 180-185, 2001. (Pubitemid 32924416)
22. Roodman GD: Regulation of osteoclast differentiation. Ann NY Acad Sci 1068: 100-109, 2006. (Pubitemid 43824141)
23. Abbas S, Clohisy JC and Abu Amer Y: Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res 21: 1041-1048, 2003. (Pubitemid 37322386)
24. AE Grigoriadis, ZQ Wang, MG Cecchini, et al: C-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448, 1994.
25. Zheng Y, Wang L, Zhang X, et al: BMP2/7 heterodimer can modulate all cellular events of the in vitro RANKL-mediated osteoclastogenesis, respectively, in different dose patterns. Tissue Eng Part A 18:621-630, 2012.
26. Anderson RD, Haskell RE, Xia H: A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7: 1034-1038, 2000. (Pubitemid 30398352)
27. Palmer GD, Gouze E, Gouze JN, Betz OB, Evans CH and Ghivizzani SC: Gene transfer to articular chondrocytes with recombinant adenovirus. Methods Mol Biol 215: 235-246, 2003.
28. Takayanagi H, Kim S, Koga T, et al: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901, 2002. (Pubitemid 35460788)
29. Novack DV and Teitelbaum SL: The osteoclast: Friend or foe? Annu Rev Pathol 3: 457-484, 2008. (Pubitemid 351488289)
30. Yagi M, Miyamoto T, Sawatani Y, et al: DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202: 345-351, 2005. (Pubitemid 41126951)
31. Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999. (Pubitemid 29168945)
32. Arai A, Mizoguchi T, Harada S, et al: Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment. J Cell Sci 125: 2910-2917, 2012.
33. Abu-Amer Y, Darwech I and Clohisy JC: Aseptic loosening of total joint replacements: Mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 9 (Suppl 1): S6, 2007.
34. Shen Z, Crotti TN, McHugh KP, et al: The role played by cellsubstrate interactions in the pathogenesis of osteoclastmediated peri-implant osteolysis. Arthritis Res Ther 8: R70, 2006.
35. Cao X and Chen D: The BMP signaling and in vivo bone formation. Gene 357: 1-8, 2005. (Pubitemid 41267309)
36. Bessa PC, Casal M and Reis RL: Bone morphogenetic proteins in tissue engineering: The road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2: 81-96, 2008.
37. Gautschi OP, Frey SP and Zellweger R: Bone morphogenetic proteins in clinical applications. ANZ J Surg 77: 626-631, 2007. (Pubitemid 47063348)
38. Kirker-Head CA, Boudrieau RJ and Kraus KH: Use of bone morphogenetic proteins for augmentation of bone regeneration. J Am Vet Med Assoc 231: 1039-1055, 2007. (Pubitemid 350013497)
39. Li G, Li Q, Lin LJ, Duan X and Zhang XQ: Slow-release recombinant human bone morphogenetic protein-2 suppresses chromium wear particle-induced osteolysis in rats. Nan Fang Yi Ke Da Xue Xue Bao 32: 391-395, 2012 (In Chinese).
40. Helgeson MD, Lehman RA Jr, Patzkowski JC, Dmitriev AE, Rosner MK and Mack AW: Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion. Spine J 11: 507-510, 2012.
41. Southwood LL, Frisbie DD, Kawcak CE, Ghivizzani SC, Evans CH and McIlwraith CW: Evaluation of Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J Orthop Res 22: 66-72, 2004. (Pubitemid 38035447)
42. Beraudi A, Stea S, Cremonini S, Visentin M and Toni A: Assessment of five interleukins in human synovial fluid as possible markers for aseptic loosening of hip arthroplasty. Artif Organs 33: 538-543, 2009.
43. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP and Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488, 2000. (Pubitemid 32038586)
44. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y and Kim HH: Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 351: 99-105, 2006. (Pubitemid 44635412)